ALS2 Funding Opportunity: Fundamental Research in Underlying Causes of Amyotrophic Lateral Sclerosis

We’re pleased to announce our participation in the Accelerating Leading-edge Science in ALS (ALS2) program (NOT-RM-20-019). ALS2 is a $25 million NIH Common Fund initiative to spur innovative research into the basic biology of amyotrophic lateral sclerosis (ALS) through the NIH Director’s Transformative Research Award. NIGMS encourages our community of basic scientists working on relevant processes to consider applying for this opportunity. ALS is a devastating disease with no known cure. The development of effective therapeutics can benefit tremendously from basic ALS research that 1.) tests highly novel concepts, 2.) brings together researchers from different scientific perspectives, and 3.) applies powerful emerging technologies from a variety of disciplines. Applications that use one or more of the following approaches are encouraged: Adapting emerging tools and technologies from neuroscience, cell biology, and other disciplines to identify what causes ALS and how the disease progresses, leading to new therapeutic strategiesAttracting new talent from a range of scientific disciplines, including cell biology, bioengineering, chemistry, biophysics, environmental health sciences, and computational scienceExploring potential similarities between ALS and other neurodegenerative disorders, including frontotemporal dementia, chronic traumatic encephalopathy, Kennedy’s disease, spinal muscular atrophy, and primary lateral sclerosis Applications must be submi...
Source: NIGMS Feedback Loop Blog - National Institute of General Medical Sciences - Category: Biomedical Science Authors: Tags: Funding Opportunities NIH Common Fund Source Type: blogs